Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, Nicolas Kahn, Veronika Müller, Michael Kreuter. The therapy of idiopathic pulmonary fibrosis: what is next?. Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019

Member's Comments

No comment yet.

Related content which might interest you: Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard Source: Eur Respir J 2015; 45: 1208-1210 Year: 2015 Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003 Severe idiopathic pulmonary fibrosis: what can be done? Source: Eur Respir Rev, 26 (145) 170047; 10.1183/16000617.0047-2017 Year: 2017 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Communicating with patients with idiopathic pulmonary fibrosis: can we do it better? Source: ERJ Open Res, 8 (1) 00422-2021; 10.1183/23120541.00422-2021 Year: 2022 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Targeted treatment of idiopathic pulmonary fibrosis: one step at a time Source: Eur Respir J 2016; 47:1321-1323 Year: 2016 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Are the gains due to pulmonary rehabilitation in idiopathic pulmonary fibrosis and other interstitial lung diseases the same? Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care Year: 2020 A first step against idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 130-131 Year: 2011 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 The changing treatment landscape in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 65-68 Year: 2015 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016